老年衰弱头颈鳞癌:大分割分段放疗对比标准放疗的非劣效随机试验
ELAN-RT 试验在法国和摩纳哥 30 个中心纳入 ≥70 岁、经老年评估为衰弱、II-IV 期不可切除头颈鳞癌患者,随机接受大分割分段放疗(HSC-RT,55 Gy/20 次)或标准分割放疗(SF-RT,70 Gy/35 次)。意向性分析中 6 个月完全局部区域缓解存活比例 HSC-RT 组 35%、SF-RT 组 33%(差异 +2%,95%CI -11 至 15),未超过 16% 非劣效界值;
要点
- HSC-RT 6 个月完全局部区域缓解存活率不劣于 SF-RT,差异 +2%(95%CI -11 至 15)。
- HSC-RT 仅应在老年评估后认为不适合 SF-RT 的衰弱老年患者中考虑。
核心结论
- 与 SF-RT 相比,HSC-RT 未降低 6 个月完全局部区域缓解存活比例,可作为衰弱老年患者的一种选择。
- 鉴于生存结果,HSC-RT 应仅提供给经老年评估认为不适合 SF-RT 的患者。
研究设计与样本
- 非劣效、多中心、开放标签、随机对照试验,在法国和摩纳哥 30 个治疗中心开展。
- 纳入 ≥70 岁、经老年评估为衰弱、II-IV 期头颈鳞癌且以治愈为目的的患者,1:1 随机分配。
- HSC-RT 组 102 例随机、101 例纳入分析;SF-RT 组 100 例;中位年龄 82 岁(IQR 77-86)。
- 主要终点为 6 个月时存活且完全局部区域缓解的比例,非劣效界值设为 16%。
主要发现
- 意向性分析:HSC-RT 组 101 例中 35 例(35%)、SF-RT 组 100 例中 33 例(33%)6 个月存活且完全局部区域缓解(差异 +2%,95%CI -11 至 15)。
- 符合方案分析:HSC-RT 组 97 例中 35 例(36%)、SF-RT 组 95 例中 33 例(35%)(差异 +1%,95%CI -12 至 15)。
- 放疗开始至放疗结束后 30 天内死亡 8 例(HSC-RT 组 5 例[5%],SF-RT 组 3 例[3%])。
关键数值与推荐
- SF-RT 方案:70 Gy,35 次,7 周。
- HSC-RT 方案:55 Gy,20 次,分两程各 2 周、中间休息 2 周。
- 非劣效界值:16%。
临床怎么用
- 对经老年评估为衰弱、不适合 SF-RT 的 ≥70 岁局部晚期头颈鳞癌患者,HSC-RT 可作为替代方案。
- 选择 HSC-RT 前应结合老年评估权衡生存结果,不应将其作为所有衰弱老年患者的标准替代。
局限性
- 开放标签设计,医生和患者未设盲。
- HSC-RT 组 1 例拒绝治疗和随访被排除,最终分析 101 例而非 102 例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard treatment for older patients (aged ≥70 years) with localised, unresectable head and neck squamous-cell carcinoma is standard fractionated radiotherapy (SF-RT). However, its high toxicity and multiple fractions lead physicians to deliver tailored hypofractionated split-course radiotherapy (HSC-RT). The aim of the study was to compare these two radiotherapy methods in older patients. METHODS: This non-inferiority, multicentre, open-label, randomised controlled trial was done in 30 treating centres (cancer centres, university and general hospitals, and private clinics) across France and Monaco. Patients aged 70 years or older, assessed as frail by geriatric evaluation, with stage II-IV head and neck squamous-cell carcinoma and in curative intent were randomly assigned (1:1) to receive either SF-RT (70 Gy, 35 fractions over 7 weeks) or HSC-RT (55 Gy, 20 fractions, two courses of 2 weeks with 2 weeks stop). Randomisation was done by minimisation, and physicians and patients were not masked to the treatment group. The primary endpoint was the proportion of patients alive with complete locoregional response at 6 months, analysed in all randomly assigned patients (intention-to-treat population). The non-inferiority margin was set at 16%. The study was sponsored by the Groupe d'Oncologie Radiothérapie Tête et Cou (GORTEC) and is registered with ClinicalTrials.gov, NCT01864850. FINDINGS: Between Oct 21, 2013, and Aug 22, 2018, 102 patients were randomly assigned to the HSC-RT group and 100 patients to the SF-RT group. One patient in the HSC-RT group refused treatment and follow-up and so was excluded, resulting in 101 patients in the HSC-RT group. Median age was 82 years (IQR 77-86); 145 (72%) were male and 56 (28%) were female. Median follow-up for overall survival was 56·6 months (IQR 41-69). In the intent-to-treat population, 35 (35%) of 101 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (33%) of 100 patients in the SF-RT group (difference +2%, 95% CI -11 to 15). In the per-protocol population, 35 (36%) of 97 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (35%) of 95 patients in the SF-RT group (difference +1%, -12 to 15). Median overall survival was 13·0 months (95% CI 10·3 to 17·0) in the HSC-RT group versus 18·9 months (14·3 to 30·9) in the SF-RT group (hazard ratio 1·32, 95% CI 0·97 to 1·81). Eight patients died between radiotherapy start and 30 days after radiotherapy end (five [5%] in the HSC-RT group and three [3%] in the SF-RT group). One patient in the HSC-RT group had a grade 4 adverse event (kidney failure), as did four in the SF-RT group (two mucositis, one septic shock, and one hemiplegia). Acute adverse events grade 3-5 occurred in 33 (36%) of 91 patients in the HSC-RT group and in 44 (47%) of 93 patients in the SF-RT group (p=0·13; difference -11%, 95% CI -25 to 3). INTERPRETATION: Compared with SF-RT, HSC-RT did not decrease the 6-month complete locoregional response rate and could be an option for frail older patients. However, given the survival results, it should only be offered to patients deemed unsuitable for SF-RT after geriatric assessment. FUNDING: French programme PAIR-VADS 2011 (sponsored by the French National Cancer Institute, Fondation ARC, and Ligue Contre le Cancer), GEMLUC, and GEFLUC.
引用
- Ortholan C, Aupérin A, Tao Y, et al. Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial. Lancet Healthy Longev. 2026. PMID: 41713468. doi:10.1016/j.lanhl.2025.100812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。